Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence

Sacha I Rothschild Department of Internal Medicine, Medical Oncology, University Hospital Basel, Basel, Switzerland Abstract: The therapeutic landscape in non-small-cell lung cancer (NSCLC) is changing. The description of molecular alterations leading to NSCLC carcinogenesis and progression (so-ca...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Rothschild SI
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/5b909e68f466420d993c0859e0797d53
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5b909e68f466420d993c0859e0797d53
record_format	dspace
spelling	oai:doaj.org-article:5b909e68f466420d993c0859e0797d532021-12-02T08:52:58ZClinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence1179-2728https://doaj.org/article/5b909e68f466420d993c0859e0797d532014-09-01T00:00:00Zhttp://www.dovepress.com/clinical-potential-of-nintedanib-for-the-second-line-treatment-of-adva-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728 Sacha I Rothschild Department of Internal Medicine, Medical Oncology, University Hospital Basel, Basel, Switzerland Abstract: The therapeutic landscape in non-small-cell lung cancer (NSCLC) is changing. The description of molecular alterations leading to NSCLC carcinogenesis and progression (so-called oncogenic driver mutations) and the development of targeted agents interfering with the tumor-promoting intracellular signaling pathways have improved the outcome for many patients with advanced/metastatic NSCLC. However, many patients with stage IV NSCLC do not have one of the targetable predictive biomarkers, and are therefore in need of classical chemotherapy. This especially applies to squamous cell cancer. A platinum-based doublet chemotherapy is the standard of care for patients with stage IV NSCLC. As second-line therapies, docetaxel, pemetrexed, and the EGFR tyrosine-kinase inhibitor erlotinib have demonstrated benefit in Phase III randomized trials. Recently, the addition of the angiokinase inhibitor nintedanib to docetaxel has proven efficacious, and is a new treatment option in the second-line setting. Preclinical and clinical data of nintedanib for the treatment of lung cancer patients are reviewed here. Keywords: nintedanib, lung cancer, angiokinase inhibitor, VEGFR, PDGF, FGFRRothschild SIDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol 2014, Iss default, Pp 51-57 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Rothschild SI Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence
description	Sacha I Rothschild Department of Internal Medicine, Medical Oncology, University Hospital Basel, Basel, Switzerland Abstract: The therapeutic landscape in non-small-cell lung cancer (NSCLC) is changing. The description of molecular alterations leading to NSCLC carcinogenesis and progression (so-called oncogenic driver mutations) and the development of targeted agents interfering with the tumor-promoting intracellular signaling pathways have improved the outcome for many patients with advanced/metastatic NSCLC. However, many patients with stage IV NSCLC do not have one of the targetable predictive biomarkers, and are therefore in need of classical chemotherapy. This especially applies to squamous cell cancer. A platinum-based doublet chemotherapy is the standard of care for patients with stage IV NSCLC. As second-line therapies, docetaxel, pemetrexed, and the EGFR tyrosine-kinase inhibitor erlotinib have demonstrated benefit in Phase III randomized trials. Recently, the addition of the angiokinase inhibitor nintedanib to docetaxel has proven efficacious, and is a new treatment option in the second-line setting. Preclinical and clinical data of nintedanib for the treatment of lung cancer patients are reviewed here. Keywords: nintedanib, lung cancer, angiokinase inhibitor, VEGFR, PDGF, FGFR
format	article
author	Rothschild SI
author_facet	Rothschild SI
author_sort	Rothschild SI
title	Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence
title_short	Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence
title_full	Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence
title_fullStr	Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence
title_full_unstemmed	Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence
title_sort	clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/5b909e68f466420d993c0859e0797d53
work_keys_str_mv	AT rothschildsi clinicalpotentialofnintedanibforthesecondlinetreatmentofadvancednonsmallcelllungcancercurrentevidence
_version_	1718398304478298112

Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence

Ejemplares similares